Mizuho Securities Starts Syndax Pharmaceuticals (SNDX) at Buy, 'Two Near-Term Commercial Opportunities With Upside Drives Our Buy'
Tweet Send to a Friend
(Updated - December 22, 2023 6:38 AM EST)
Mizuho Securities analyst Mara Goldstein initiates coverage on Syndax Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Mizuho Securities analyst Mara Goldstein initiates coverage on Syndax Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
